Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06788938 | Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms | PHASE2 | RECRUITING | 29 | — | — | Mar 21, 2025 | Apr 24, 2029 | May 18, 2026 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| Tarlatamab treatment | EXPERIMENTAL | Tarlatamab will be administered as a 60-minute intravenous (IV) |
| Name | Type | Description |
|---|---|---|
| Tarlatamab treatment | DRUG | * 1 mg step dose on cycle 1 day 1 (C1D1) * 10 mg target dose on cycle 1 day 8 (C1D8), and cycle 1 day 15 (C1D15) in a 28-day cycle. * 10 mg Q2W subsequently (i.e., C2 + D1/D15 dosing) in a 28-day cycle |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: 1. Participant has provided informed consent prior to initiation of any study specific activities/procedures. 2. Male or female ≥ 18 years of age and willing and able to provide i...